Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: A cost-minimization analysis

Journal of Hospital Infection

Volumn 33, Issue 1, 1996, Pages 35-48

  Wakerly, L ^a   Craig, A M ^a   Malek, M ^a   Hoffmeyer, U ^a   Lloyd, A ^a   Valette, F ^a   Phillips, R ^a   Zabihollah, M ^a  

^a NONE

Author keywords

Cost minimization; Fluconazole; Immunocompromised patients; Prophylaxis

Indexed keywords

AMPHOTERICIN; CEFTAZIDIME; FLUCONAZOLE; GENTAMICIN; HYDROCORTISONE; NYSTATIN; PIPERACILLIN; POLYENE; POTASSIUM; VANCOMYCIN;

ARTICLE; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CLINICAL EXAMINATION; CLINICAL TRIAL; COST CONTROL; DRUG CHOICE; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; INTERVIEW; INTRAVENOUS DRUG ADMINISTRATION; MYCOSIS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0029992512     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-6701(96)90027-4     Document Type: Article

References (23)

1. Klastersky J. Febrile neutropenia. Support Care Cancer 1993; 1: 233-239.
2. van t'Wout JW. Itraconazole in neutropenic patients. Chemotherapy 1992; 38 (Supp. 1): 23-26.
3. Philpott-Howard JN, Wade JJ, Mufti GJ et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993; 31: 973-984.
4. Pons VG. Comparative clinical study of oral suspension fluconazole versus topical liquid oral nystatin in the treatment of oropharyngeal candidiasis in AIDS. Update in the Management of Fungal Infections, XII Congress of ISHAM, Adelaide, Australia, 15 March 1994.
5. Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916.
6. Menichetti F, Del-Favero A, Martino P et al. Preventing fungal infection in neutropenic patients with acute leukaemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994; 120: 913-918.
7. Chandrasekar PH, Gatny CM. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients, J Antimicrob Ther 1994; 33: 309-318.
8. Winston DJ, Chandrasekar HM, Lazarus HM et al. Fluconazole prophylaxis of fungal infections in patients with acute leukaemia. Results of a randomized, placebo-controlled, double-blind, multicentre trial. Ann Intern Med 1993; 118: 495-503.
9. Cesaro S, Rossetti F, Perilongo G et al. Fluconazole prophylaxis and Candida fungemia in neutropenic children with malignancies. Haematologica 1993; 78: 249-251.
10. Cap J, Mojzesova A, Kayserova E et al. Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in paediatric patients with cancer. Chemotherapy 1993; 39: 438-442.
11. Finke R. Comparison of oral fluconazole and amphotericin B prophylaxis against fungal infections in the neutropenic phase of patients treated with anti-leukaemic agents. Mycoses 1990; 33 (Supp. 1): 42-54.
12. Buchanan AG, Riben PD, Rayner EN et al. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. Clin Invest Med 1985; 8: 139-147.
13. Wingard JR, Merz WG, Rinaldi MG, Miller CB et al. Association of torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993; 37: 1847-1849.
14. Wingard JR, Merz WG, Rinaldi MG, Johnson TR et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-1277.
15. Ellis ME, Clink H, Halim MA et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol 1994; 13: 3-11.
16. Perfect JR, Klotman ME, Gilbert CC et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone-marrow transplant recipients. J Infect Dis 1992; 165: 891-897.
17. O'Donnell MR, Schmidt GM, Tetmeier BR et al. Prediction of systemic fungal infection in allogenic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994; 12: 827-834.
18. Barber N, Hoffmeyer U. Comparison of the cost-effectiveness of administering heparin subcutaneously or intravenously for the treatment of deep vein thrombosis. Ann R Coll Surg Engl 1993; 75: 430-433.
19. Barber N, Hoffmeyer U. Heparin administration using prefilled syringes or ampoules: a comparative cost-effectiveness study. Int J Pharm Practice 1993; March: 15-17.
20. Department of Health. NHS Management Executive Advance Letter (NM) 3/94, 1994; 3 March.
21. Department of Health. NHS Management Executive Advance Letter (MD) 3/94, 1994; 17 March.
22. Anon. British National Formulary, No. 28, 1994; September.
23. Davey PT, Dodd S, Malek M. Audit of intravenous antibiotic administration. Scottish Office National Health Service (CRAG) 1991; Paper No. 13.